PMID- 36249645
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 9
DP  - 2022 Sep
TI  - Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With 
      Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review.
PG  - e29069
LID - 10.7759/cureus.29069 [doi]
LID - e29069
AB  - Type 2 diabetes mellitus (T2DM) is a significant cause of cardiovascular deaths 
      worldwide. There are many oral antihyperglycemic drugs available to treat 
      diabetic patients. Among them, sodium-glucose cotransporter 2 (SGLT2) inhibitors 
      provide effective treatment in all stages of T2DM regardless of blood glucose 
      levels and benefit the cardiovascular system. SGLT2 inhibitors have an additional 
      diuretic effect that reduces blood pressure and hospitalizations and improves 
      heart failure outcomes. This study will assess the efficacy of SGLT2 inhibitors 
      in cardiovascular outcomes in patients with T2DM and cardiovascular disease. Our 
      systematic review followed the Preferred Reporting Items for Systematic Reviews 
      and Meta-Analyses (PRISMA) guidelines and involved a literature search utilizing 
      PubMed and Google Scholar databases. In addition, we thoroughly searched for 
      studies conducted in the last 10 years that corresponded with our outlined 
      inclusion and exclusion criteria. Our search yielded 779 articles. The articles 
      were then quality-checked before inclusion. We ultimately selected six randomized 
      controlled trials and two meta-analyses of research articles after applying the 
      inclusion and exclusion criteria. Our research study included 91,796 T2DM and 
      cardiovascular disease patients. We examined cardiovascular outcomes among these 
      T2DM patients, such as major adverse cardiac events (MACE), blood pressure, heart 
      failure, and hospitalizations. Our study showed that SGLT2 inhibitors 
      significantly reduce weight and blood pressure due to their natriuretic effects. 
      In addition, they also improve heart failure symptoms and reduce 
      hospitalizations.
CI  - Copyright (c) 2022, Sarker et al.
FAU - Sarker, Aditi
AU  - Sarker A
AD  - Family Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Ramesh, Adarsh Srinivas
AU  - Ramesh AS
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Munoz, Carlos
AU  - Munoz C
AD  - General Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Jamil, Dawood
AU  - Jamil D
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Tran, Hadrian Hoang-Vu
AU  - Tran HH
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Mansoor, Mafaz
AU  - Mansoor M
AD  - Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Butt, Samia Rauf
AU  - Butt SR
AD  - General Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Satnarine, Travis
AU  - Satnarine T
AD  - Pediatrics, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Ratna, Pranuthi
AU  - Ratna P
AD  - General Medicine, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
FAU - Hamid, Pousette
AU  - Hamid P
AD  - Neurology, California Institute of Behavioral Neurosciences & Psychology, 
      Fairfield, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220912
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9554929
OTO - NOTNLM
OT  - cardiovascular complications
OT  - heart failure.
OT  - oral hypoglycemic agents
OT  - sglt 2 inhibitors
OT  - type 2 dm
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/09/12
CRDT- 2022/10/17 05:26
PHST- 2022/06/29 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/17 05:26 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/09/12 00:00 [pmc-release]
AID - 10.7759/cureus.29069 [doi]
PST - epublish
SO  - Cureus. 2022 Sep 12;14(9):e29069. doi: 10.7759/cureus.29069. eCollection 2022 
      Sep.